Entera Bio Ltd. (ENTX) Financial Analysis & Valuation | Quarter Chart
Entera Bio Ltd. (ENTX)
ENTXPrice: $1.27
Fair Value: 🔒
🔒score
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment ... more
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commerci... more
Description
Shares
| Market Cap | $62.52M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | IL | CEO | Miranda J. Toledano |
| IPO Date | 2018-06-28 | CAGR | — |
| Employees | 18 | Website | www.enterabio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ENTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $20.82M | P/E Ratio | -4.88 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-0.26 | EPS Growth 1Y | -110.34% |
| EPS Growth 3Y | -98.5% | EPS Growth 5Y | -101.45% |
| Revenue Growth 1Y | -97.29% | Gross Margin | -0.06% |
| Operating Margin | -19.69% | Profit Margin | -20.19% |
| ROE | -0.17% | ROA | -0.14% |
| ROCE | -0.15% | Current Ratio | 10.83 |
| Quick Ratio | 10.83 | Cash Ratio | 5.46 |
| Debt/Equity | 0.01 | Interest Coverage | -348.86 |
| Altman Z Score | 7.06 | Piotroski Score | 3 |